Evidence map›Paper›PMID 42439623›Full record

ArticleCells2026

Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections.

Ryan Z Z Lew, Douglas J W Tay, Jocelyn W X Ong, Jing Hui Low, Jing Liu, De Yun Wang, Justin J H Chu, Anand Kumar Andiappan, Kai Sen Tan, Vincent T K Chow

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ryan Z Z LewDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117545, Singapore.ORCID 0000-0002-7027-730X
Douglas J W TayDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117545, Singapore.
Jocelyn W X OngSingapore Immunology Network, Agency for Science, Technology and Research, Biopolis, Singapore 138648, Singapore.
Jing Hui LowSingapore Immunology Network, Agency for Science, Technology and Research, Biopolis, Singapore 138648, Singapore.
Jing LiuDepartment of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 119228, Singapore.
De Yun WangInfectious Diseases Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117597, Singapore.ORCID 0000-0002-0909-2963
Justin J H ChuDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117545, Singapore.ORCID 0000-0002-1673-6819
Anand Kumar AndiappanSingapore Immunology Network, Agency for Science, Technology and Research, Biopolis, Singapore 138648, Singapore.ORCID 0000-0002-8442-1544
Kai Sen TanDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117545, Singapore.
Vincent T K ChowDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117545, Singapore.ORCID 0000-0003-2634-6213

Funding

National University of Singapore E-57100081601
6 · The paper itself

Abstract

The COVID-19 pandemic highlighted the urgent need to develop effective and broad-spectrum antiviral therapies against coronaviruses. One strategy to address this concern is a combination therapy using repurposed drugs against zoonotic viruses with pandemic potential. We previously demonstrated that the combination of Remdesivir and Ivermectin is highly potent and synergistic in inhibiting the replication of murine hepatitis virus (MHV) in RAW264.7 macrophages. This study investigated the interactions between the drug combination, coronavirus and host by proteomics and RNA sequencing of MHV-infected H2.35 murine liver epithelial cells. Time-of-addition and time-of-removal assays suggested that the drug combination likely affected the synthesis of viral RNA and viral protein. This combination drastically diminished the live virus titer greater than the respective monotherapies in MHV-infected H2.35 cells (by ~4 log

Indexed as

Adenosine MonophosphateAlanineAntiviral AgentsCoronavirus InfectionsCOVID-19 Drug TreatmentIvermectinMurine hepatitis virusSARS-CoV-2AnimalsCell LineChlorocebus aethiopsDrug SynergismDrug Therapy, CombinationEpithelial CellsHumansMiceAdenosine MonophosphateAlanineAntiviral AgentsIvermectinremdesivirRNA, Viralcombination therapyhost pathwaysIvermectinmurine hepatitis virusproteomicsRemdesivirrepurposed drugsSARS-CoV-2transcriptomics

Identifiers

PMID42439623
PMCPMC13359856

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.